APA

Schröder C. P., de Vries E. G., Mulder N. H., Willemse P. H., Sleijfer D. T., Hospers G. A. & van der Graaf W. T. (19990916). Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. : The Journal of antimicrobial chemotherapy.

Chicago

Schröder C P, de Vries E G, Mulder N H, Willemse P H, Sleijfer D T, Hospers G A and van der Graaf W T. 19990916. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. : The Journal of antimicrobial chemotherapy.

Harvard

Schröder C. P., de Vries E. G., Mulder N. H., Willemse P. H., Sleijfer D. T., Hospers G. A. and van der Graaf W. T. (19990916). Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. : The Journal of antimicrobial chemotherapy.

MLA

Schröder C P, de Vries E G, Mulder N H, Willemse P H, Sleijfer D T, Hospers G A and van der Graaf W T. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. : The Journal of antimicrobial chemotherapy. 19990916.